Feasibility and willingness-to-pay for integrated community-based tuberculosis testing.
BMC Infect. Dis., 11:305 (2011)
An integrated alcohol abuse and medical treatment model for patients with hepatitis C.
Dig. Dis. Sci., Apr;57(4):1083-91 (2012)
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.
Dig. Dis. Sci., Aug;57(8):2213-21 (2012)
Erratum to: The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection.
Dig. Dis. Sci., Sep;57(9):2479 (2012)
A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.
Am. J. Med., Mar;124(3):276.e1-7 (2011)
Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population.
AIDS Res. Hum. Retroviruses., Oct;23(10):1230-6 (2007)
Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis.
Clin. Chest Med., Jun;30(2):337-53, vii-viii (2009)
Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
J. Antimicrob. Chemother., Jun;65(6):1094-9 (2010)
Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States.
AIDS Patient Care STDS., Sep;24(9):539-43 (2010)
Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
J. Antimicrob. Chemother., Oct;65(10):2063-9 (2010)